Klivira
Request demo

Aetna Opdivo Prior Authorization: Accelerating Approvals for Nivolumab

Navigating the complexities of Aetna Opdivo prior authorization is a critical operational challenge for revenue cycle and prior authorization teams. Klivira streamlines this process, ensuring timely approvals for this high-volume oncology biologic.

Opdivo (nivolumab) is an immune checkpoint inhibitor frequently requiring prior authorization across Aetna's commercial, Medicare Advantage, and Medicaid managed care plans. Efficiently managing these authorizations is essential for patient access and revenue integrity. Understanding Aetna's specific submission channels, policy criteria, and electronic capabilities is key to minimizing delays and denials.

Aetna Prior Authorization Channels for Opdivo (Nivolumab)

Aetna's submission channels for Opdivo prior authorization depend on whether the drug is covered under the medical or pharmacy benefit. For medical-benefit Opdivo, requests are typically routed via the Availity provider portal or through X12 278 transactions via clearinghouses. Pharmacy-benefit Opdivo, administered through CVS Caremark, routes through ePA partners like CoverMyMeds or Surescripts for retail, or CVS Caremark's direct portal for mail-order specialty cases.

Key Aetna Clinical Policy Bulletins (CPBs) for Oncology Biologics

  • Aetna publishes medical necessity criteria for oncology biologics, including Opdivo, within its public Clinical Policy Bulletins (CPBs).
  • CPBs are versioned and dated, providing the canonical identifier for Aetna's coverage policies.
  • Criteria often reference external sources like the NCCN compendium for oncology indications and off-label use support.
  • Reviewing the specific CPB applicable to nivolumab is crucial for understanding indications, dosing, and step therapy requirements.

Common Denial Reasons for Opdivo with Aetna

Denials for Opdivo prior authorizations with Aetna often stem from insufficient documentation of medical necessity, lack of adherence to step therapy protocols, or off-label use without adequate compendium support. Other reasons can include site-of-service mismatches or benefit exclusions. Aetna returns denial reasons via X12 835/277 transactions or portal status updates, utilizing standard CARC and RARC vocabularies.

Optimizing Opdivo PA Submission for Aetna

  • Verify benefit category (medical vs. pharmacy) to select the correct submission channel.
  • Ensure all clinical documentation aligns with the latest Aetna Clinical Policy Bulletin (CPB) for nivolumab.
  • Provide clear evidence of diagnosis, prior therapies, and patient-specific factors supporting medical necessity.
  • Leverage electronic submission methods (ePA, X12 278) to reduce manual processing and potential errors.
  • Proactively address step therapy requirements and document any contraindications or intolerances to preferred agents.

Aetna's Turnaround Times and Electronic PA Posture

Aetna's prior authorization turnaround times are governed by state regulations, NCQA Utilization Management accreditation standards, and for Medicare Advantage and Medicaid lines, CMS-0057-F. While Aetna supports ePA for pharmacy benefits via partners like CoverMyMeds and Surescripts, medical-benefit ePA is more fragmented. Klivira's platform integrates with Aetna's various submission points to help providers meet these diverse requirements and accelerate decision-making.

Frequently asked questions

How do I submit an Aetna Opdivo prior authorization request?

For medical-benefit Opdivo, submissions are primarily through the Availity provider portal or via X12 278 transactions. For pharmacy-benefit Opdivo (handled by CVS Caremark), requests can be submitted through CoverMyMeds or Surescripts ePA platforms, or directly via the CVS Caremark provider portal for mail-order scenarios.

Where can I find Aetna's medical necessity criteria for Opdivo?

Aetna publishes its medical necessity criteria for Opdivo within its public Clinical Policy Bulletins (CPBs). These documents specify approved indications, dosing, and any step therapy requirements. It is crucial to consult the most current version of the relevant CPB.

What are common reasons for Aetna Opdivo PA denials?

Common denial reasons for Opdivo with Aetna include insufficient documentation of medical necessity, failure to meet step therapy requirements, lack of compendium support for off-label indications, or issues with site-of-service. Ensuring comprehensive documentation aligned with Aetna's CPBs is vital.

Does Aetna support electronic prior authorization (ePA) for Opdivo?

Aetna supports ePA for pharmacy-benefit Opdivo through partners like CoverMyMeds and Surescripts. For medical-benefit Opdivo, electronic submission is primarily via the Availity portal or X12 278 transactions. Klivira automates data submission to these various electronic channels.

How can Klivira help with Aetna Opdivo prior authorizations?

Klivira automates the submission and tracking of Aetna Opdivo prior authorizations by integrating directly with your EMR and Aetna's various payer portals and electronic channels. This reduces manual effort, improves data accuracy, and helps accelerate approval times for critical oncology treatments.

Related coverage

Other opdivo prior authorization by payer

Other opdivo prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo